23AndMe’s Future Hangs in the Balance as Restructuring Decision Looms

Core Business Divestiture Leaves Company Transformed

The survival of 23AndMe Holding Co. hangs by a thread as the company navigates Chapter 11 bankruptcy proceedings under its new corporate identity, Chrome Holding Co. A pivotal court hearing scheduled for November 19 will determine the fate of what was once considered a pioneering force in biotechnology.

In a dramatic restructuring move, the company has sold off its fundamental operations. The transaction, finalized on July 14, saw TTAM Research Institute acquire 23AndMe’s personal genomics services, research platforms, and Lemonaid Health business for a total of $305 million. This divestiture stripped away 84% of the company’s former revenue stream, fundamentally altering its nature.